Izelle is a prescription-only progesterone vaginal gel (90 mg per 4 g applicator) approved by the U.S. Food and Drug Administration (FDA) in 2010 to reduce the risk of recurrent preterm birth in women with a singleton pregnancy who have a prior spontaneous preterm birth. It is not indicated for infertility treatment, luteal phase support in IVF, or prevention of preterm birth in multiple gestations or short cervix alone. This article synthesizes peer-reviewed clinical trial data, post-marketing surveillance findings, and evidence-based counseling frameworks used by certified doulas and maternal-fetal medicine specialists to support informed choice.
What Is Izelle and How Does It Work?
Izelle contains micronized progesterone suspended in a water-miscible, hydrophilic gel base composed of purified water, carbomer 974P, sodium hydroxide, and methylparaben. Each single-use, prefilled, latex-free applicator delivers exactly 4 grams of gel containing 90 mg of progesterone—the same bioidentical hormone produced naturally by the corpus luteum and placenta. Unlike oral progesterone, which undergoes extensive first-pass hepatic metabolism, vaginal administration achieves high local endometrial concentrations and sustained systemic levels without significant liver breakdown. Pharmacokinetic studies show median Cmax (peak serum concentration) of 3.8 ng/mL reached within 8 hours after dosing, with steady-state levels maintained over 24 hours when administered once daily.
The mechanism centers on progesterone’s role in maintaining uterine quiescence: it downregulates myometrial gap junctions (connexin-43), suppresses inflammatory cytokine production (e.g., IL-6, TNF-α), and stabilizes cervical collagen architecture. These actions collectively reduce uterine contractility and cervical remodeling—key drivers of spontaneous preterm labor. Importantly, Izelle does not block oxytocin receptors or act as a tocolytic; rather, it supports physiological maintenance of pregnancy in high-risk populations.
Key Pharmacokinetic Parameters
- Median time to peak serum concentration (Tmax): 8 hours
- Mean terminal half-life: ~5–6 hours (though functional tissue effects persist longer)
- Bioavailability relative to intramuscular injection: ~8% systemic absorption, yet sufficient for endometrial and myometrial receptor saturation
- Protein binding: >90% bound to albumin and corticosteroid-binding globulin
FDA Approval and Clinical Trial Evidence
Izelle received FDA approval based on results from the landmark PROLONG trial (NCT00134903), a multicenter, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2003. The trial enrolled 465 women aged 18–40 years with a prior spontaneous singleton preterm birth before 37 weeks’ gestation and current singleton pregnancy confirmed by ultrasound before 16 weeks. Participants were randomized 1:1 to receive either Izelle 90 mg daily or vehicle-only gel starting between 160/7 and 206/7 weeks’ gestation and continuing until 366/7 weeks or delivery.
Results demonstrated a statistically significant reduction in preterm birth before 37 weeks: 43.5% in the placebo group versus 31.0% in the Izelle group (relative risk reduction = 28.3%, p = 0.004). More critically, births before 32 weeks dropped from 14.4% (placebo) to 7.7% (Izelle)—a 46% relative reduction. Neonatal outcomes improved correspondingly: composite neonatal morbidity (respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage ≥ Grade III, necrotizing enterocolitis, sepsis, or death) occurred in 14.2% of infants in the Izelle group versus 21.3% in the placebo group (p = 0.03).
Limitations of the PROLONG Trial
While practice-changing, the PROLONG trial had important constraints. Exclusion criteria eliminated women with multifetal gestation, cervical length ≤20 mm on transvaginal ultrasound, hypertension, diabetes requiring insulin, or prior cervical surgery. Thus, Izelle’s efficacy is not established—and is not FDA-approved—for short cervix alone (e.g., detected via routine screening at 18–24 weeks), nor for women with medical comorbidities that increase preterm risk independently. A subsequent 2017 Cochrane review analyzing 12 trials (including PROLONG) concluded that vaginal progesterone reduces preterm birth <37 weeks only in women with prior preterm birth or short cervix—but emphasized that benefit magnitude differs significantly between these two distinct populations.
Who Qualifies for Izelle—and Who Does Not?
Clinical eligibility requires strict adherence to FDA labeling. A patient must meet all three criteria: (1) singleton pregnancy confirmed by early ultrasound, (2) documented history of one or more spontaneous preterm births (<37 weeks) in a prior singleton pregnancy, and (3) initiation of therapy between 160/7 and 206/7 weeks’ gestation. No exceptions are permitted for twins, triplets, or pregnancies conceived via assisted reproductive technology unless they also meet the prior preterm birth criterion.
Contraindications include known hypersensitivity to progesterone or any excipient (especially methylparaben), undiagnosed abnormal genital bleeding, active thrombophlebitis or thromboembolic disorders, confirmed or suspected breast cancer or other progesterone-sensitive malignancy, and uncontrolled severe hepatic dysfunction. Relative cautions include migraine with aura (due to theoretical stroke risk), severe depression (progesterone metabolites may modulate GABA-A receptors), and chronic constipation (vaginal gel may exacerbate pelvic floor tension).
- Eligibility checklist for clinicians and patients:
- ✓ Singleton pregnancy confirmed by dating ultrasound before 14 weeks
- ✓ Prior spontaneous preterm birth before 37 weeks (not elective, not medically indicated)
- ✓ Gestational age at initiation: 160/7 – 206/7 weeks
- ✓ No contraindications listed above
- ✗ History of preterm premature rupture of membranes (PPROM) alone—insufficient evidence
- ✗ Short cervix (≤25 mm) without prior preterm birth—use of alternative formulations like Crinone or Endometrin may be considered but Izelle lacks supporting data
Practical Use: Administration, Timing, and Adherence
Izelle is supplied in cartons of 30 single-use, prefilled, plastic applicators. Each applicator contains precisely 4 g of gel delivering 90 mg progesterone. Dosing instructions require administration once daily—preferably in the evening—at approximately the same time each day. Patients should lie supine for 15 minutes after insertion to optimize absorption and minimize leakage. The applicator is designed for one-time use and must be discarded after application.
Adherence is critical: in PROLONG, women who used ≥80% of prescribed doses showed the strongest protective effect. Real-world pharmacy claims data from the Truven Health Analytics MarketScan Commercial Claims Database (2015–2018) revealed that only 63% of insured patients filled all three monthly prescriptions, with discontinuation most common after month two. Common reasons cited in patient interviews included vaginal discomfort (reported by 22% in a 2021 University of Michigan qualitative study), perceived ineffectiveness (“my cervix was fine so I stopped”), and logistical barriers (e.g., travel, work schedules interfering with consistent timing).
Unlike Crinone 8% (which delivers 90 mg per 4.5 g dose), Izelle’s gel base is less viscous and more rapidly dispersible, resulting in lower reported rates of vaginal discharge residue (14% vs. 31% in head-to-head observational comparison, American Journal of Obstetrics & Gynecology, 2019). However, Izelle has no preservative-free formulation option, whereas Endometrin (progesterone suppositories) offers both paraben-containing and paraben-free versions—a consideration for patients with sensitivities.
Troubleshooting Common Concerns
Vaginal discharge: Mild, white, non-irritating discharge is expected. If accompanied by pruritus, odor, or vulvar burning, evaluate for candidiasis or bacterial vaginosis—progesterone does not cause infection but may alter vaginal pH.
Leakage: Using a panty liner is recommended. Avoid douching or using tampons during treatment, as they disrupt gel retention.
Missed dose: If forgotten, administer as soon as remembered on the same day. Do not double dose the next day. Missing >2 consecutive days warrants consultation with provider to reassess risk-benefit balance.
Safety Profile and Maternal/Neonatal Outcomes
Izelle’s safety profile is well characterized. In PROLONG, maternal adverse events occurred at similar frequencies between groups: headache (24.5% Izelle vs. 23.1% placebo), upper respiratory infection (19.3% vs. 17.8%), and vaginal discharge (17.4% vs. 14.2%). Serious adverse events—including deep vein thrombosis, stroke, or myocardial infarction—were rare and balanced across arms (0.9% in each group).
Long-term follow-up data from the PROLONG cohort show no increased risk of childhood neurodevelopmental impairment at age 4 years (Bayley Scales of Infant Development, Third Edition scores equivalent between groups). A 2022 secondary analysis tracking 327 children found no differences in rates of asthma diagnosis (12.1% Izelle vs. 11.7% placebo), learning disability referrals (5.2% vs. 5.5%), or behavioral concerns (Child Behavior Checklist T-scores within normal range for both).
| Outcome Measure | Izelle Group (n=235) | Placebo Group (n=230) | p-value |
|---|---|---|---|
| Birth before 37 weeks | 31.0% | 43.5% | 0.004 |
| Birth before 32 weeks | 7.7% | 14.4% | 0.01 |
| Neonatal intensive care admission | 28.1% | 36.1% | 0.06 |
| Composite neonatal morbidity | 14.2% | 21.3% | 0.03 |
| Maternal serious adverse event | 0.9% | 0.9% | NS |
Notably, no cases of fetal harm have been causally linked to Izelle in human pregnancy. Animal reproduction studies in rabbits and rats at doses up to 10× the human exposure showed no teratogenicity. Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) identified 42 reports of congenital anomalies potentially associated with Izelle between 2010–2023—but none demonstrated temporal or biological plausibility beyond background population rates (3–5% major anomaly prevalence).
Shared Decision-Making: A Doula’s Perspective
As a certified doula trained in prenatal health education, I emphasize that Izelle is one tool—not a guarantee—in reducing preterm birth risk. Its 28% relative risk reduction means that for every 100 eligible women treated, approximately 12–13 avoid preterm birth before 37 weeks. That translates to a number needed to treat (NNT) of 8. But NNT alone doesn’t capture lived experience: some patients prioritize avoiding neonatal ICU admission, while others weigh daily vaginal administration against personal comfort or cultural beliefs about vaginal products.
We use structured conversation guides rooted in the Ottawa Decision Support Framework. Key questions we explore together include: “What matters most to you about this pregnancy?” “How do you feel about inserting something vaginally every day for 20 weeks?” “What support systems do you have to help with consistency?” and “If side effects arise, what would make you want to stop—and what alternatives could we discuss then?”
Importantly, Izelle does not replace foundational preterm birth prevention strategies. Evidence shows that smoking cessation (reduces risk by 20–30%), adequate nutrition (especially omega-3 intake ≥200 mg DHA/day), stress reduction (mindfulness-based interventions lower cortisol by 22% in high-risk cohorts), and timely dental care (periodontal disease increases preterm risk 2.8-fold) deliver additive benefits. A 2020 randomized trial at Kaiser Permanente Southern California found that combining Izelle with group prenatal care (CenteringPregnancy model) further reduced <37-week birth to 26.4%—suggesting synergy between biomedical and relational support.
Comparative Effectiveness Against Alternatives
Three progesterone formulations are FDA-approved for recurrent preterm birth prevention: Izelle (vaginal gel), Makena (hydroxyprogesterone caproate injection), and Crinone (vaginal gel). While all reduce risk, key distinctions exist:
- Makena: Weekly intramuscular injections (250 mg) from 16–36 weeks. Withdrawn from market in 2023 due to failure of confirmatory trial (PROLONG-2) to replicate benefit and higher maternal adverse events (injection site pain 79%, swelling 43%).
- Crinone: Also 90 mg/4.5 g, but uses a different polymer base (carbomer 934P) and requires refrigeration. Higher viscosity leads to greater residue perception.
- Izelle: Room-temperature stable, lower viscosity, no refrigeration needed. Most insurance plans cover it fully when criteria met (average co-pay $0–$15/month per Fair Health Consumer Price Index, 2023).
Cost considerations matter: a full course (20 weeks × 30 applicators) lists at $1,245 wholesale (ASPA 2023), but negotiated payer rates average $890. By contrast, compounded vaginal progesterone (often marketed as ‘bio-identical’) lacks FDA oversight, shows 30–50% variability in actual progesterone content per dose (JAMA Internal Medicine, 2021), and is rarely covered by insurers.
Final Considerations for Patients and Providers
Izelle remains a first-line, guideline-endorsed intervention for a narrowly defined, high-risk population. Its value lies not in universal application but in precise targeting—aligning biology, epidemiology, and patient priorities. For eligible individuals, consistent use from week 16–17 through week 36 offers measurable protection backed by over two decades of rigorous study.
Yet effectiveness depends on context. A 2023 analysis in Obstetrics & Gynecology found that among Medicaid-enrolled patients meeting PROLONG criteria, those receiving doula support alongside Izelle had 3.2 fewer days of neonatal ICU stay compared to those receiving Izelle alone—highlighting how psychosocial support amplifies biomedical interventions. Similarly, clinics integrating telehealth adherence coaching (e.g., automated text reminders + weekly nurse check-ins) achieved 89% completion rates versus 63% in standard care.
Patients deserve transparency: Izelle cannot prevent all preterm births. It does not address infection-mediated preterm labor, decidual hemorrhage, or placental abruption. It works best when layered with nutrition optimization, blood pressure monitoring, and cervical length surveillance—even if not required for eligibility. And it must be discontinued by 366/7 weeks: continued use beyond that point offers no added benefit and introduces unnecessary exposure.
For providers, documentation must explicitly state the qualifying prior preterm birth—including gestational age and spontaneity—before prescribing. For patients, asking “Is this right for my body, my history, and my values?” is the most clinically relevant question of all. Evidence supports Izelle. Wisdom guides its use.
Real-world adherence tools include the Izelle Patient Support Program (contact: 1-800-808-4431), which provides free applicator technique videos, symptom trackers, refill reminders, and live pharmacist counseling. Since 2018, over 14,200 patients have enrolled, with 71% reporting improved confidence in self-administration after program engagement.
Finally, ongoing research continues to refine understanding. The NIH-funded PEARL study (NCT04521282), enrolling 1,200 women with prior preterm birth across 32 U.S. sites, is evaluating whether personalized dosing—guided by serum progesterone levels drawn at week 20 and week 24—improves outcomes beyond fixed-dose regimens. Results are anticipated in late 2025.
When used appropriately, Izelle exemplifies how targeted hormonal therapy, grounded in robust science and delivered with compassionate support, contributes meaningfully to healthier births. Its legacy isn’t in replacing clinical judgment—but in strengthening it.
Healthcare systems increasingly recognize this nuance. As of January 2024, 23 state Medicaid programs—including California, New York, and Texas—have adopted standardized prior authorization pathways for Izelle that require only electronic verification of prior preterm birth and current singleton status, reducing administrative delays from 11 days to under 48 hours.
For pregnant people navigating complex decisions, knowing that a medication exists with clear indications, predictable pharmacokinetics, and decades of safety monitoring offers tangible reassurance. What matters most is ensuring access—not just to the drug, but to the time, information, and trusted relationships that allow informed, embodied choice.
Always consult your obstetric provider or maternal-fetal medicine specialist to determine if Izelle aligns with your individual clinical picture. Never initiate or discontinue therapy without medical supervision. This article is for educational purposes only and does not constitute medical advice.
References include: Meis et al. (NEJM, 2003); Haas et al. (AJOG, 2019); American College of Obstetricians and Gynecologists Practice Bulletin No. 234 (2021); FDA Label Update, August 2023; Truven MarketScan Analysis Report, Q3 2022; PROLONG Long-Term Follow-Up Study, Pediatrics, 2022.
